学术探索
学术期刊
新闻热点
数据分析
智能评审

Contlicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications: The Tort Bar and Editorial Oversight of Medical Journals

被引：45
作者：
Hirsch, Laurence J.
机构：
来源：
MAYO CLINIC PROCEEDINGS | 2009年 / 84卷 / 09期
关键词：
CONFLICTS-OF-INTEREST; MARKET-DRIVEN RESEARCH; RANDOMIZED-TRIALS; GASTROINTESTINAL TOXICITY; PHARMACEUTICAL-INDUSTRY; MYOCARDIAL-INFARCTION; RHEUMATOID-ARTHRITIS; CLINICAL-TRIALS; THE-LANCET; ROSIGLITAZONE;
D O I：
10.4065/84.9.811
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：811 / 821
页数：11
相关论文
共 137 条
[91]  
Molenberghs G, 2005, JAMA-J AM MED ASSOC, V294, P2575, DOI 10.1001/jama.294.20.2575-b
[92]   Publication bias: A brief review for clinicians [J].
Montori, VM ;
Smieja, M ;
Guyatt, GH .
MAYO CLINIC PROCEEDINGS, 2000, 75 (12) :1284-1288
[93]   Prevalence of honorary and ghost authorship in Cochrane reviews [J].
Mowatt, G ;
Shirran, L ;
Grimshaw, JJM ;
Rennie, D ;
Flanagin, A ;
Yank, V ;
MacLennan, G ;
Gotzsche, PC ;
Bero, LA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (21) :2769-2771
[94]   Rosiglitazone: A thunderstorm from scarce and fragile data [J].
Mulrow, Cynthia D. ;
Cornell, John E. ;
Localio, A. Russell .
ANNALS OF INTERNAL MEDICINE, 2007, 147 (08) :585-587
[95]  
*NAT AC I MED, 2009, CONFL INT MED RES ED
[96]  
*NAT PUBL GROUP, 2008, NAT BIOTECHNOL, V26, P476
[97]  
Nissen SE, 2007, NEW ENGL J MED, V357, P100
[98]   Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes (vol 356, pg 2457, 2007) [J].
Nissen, Steven E. ;
Wolski, Kathy .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (24) :2457-2471
[99]  
O'Keefe JH, 2008, MAYO CLIN PROC, V83, P867, DOI 10.4065/83.8.867
[100]  
Ong HT, 2008, JAMA-J AM MED ASSOC, V300, P903, DOI 10.1001/jama.300.8.903-b
567891011121314